These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 26267324)

  • 1. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy.
    Riquelme I; Saavedra K; Espinoza JA; Weber H; García P; Nervi B; Garrido M; Corvalán AH; Roa JC; Bizama C
    Oncotarget; 2015 Sep; 6(28):24750-79. PubMed ID: 26267324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy in gastric cancer.
    Thiel A; Ristimäki A
    APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
    Lei Z; Tan IB; Das K; Deng N; Zouridis H; Pattison S; Chua C; Feng Z; Guan YK; Ooi CH; Ivanova T; Zhang S; Lee M; Wu J; Ngo A; Manesh S; Tan E; Teh BT; So JB; Goh LK; Boussioutas A; Lim TK; Flotow H; Tan P; Rozen SG
    Gastroenterology; 2013 Sep; 145(3):554-65. PubMed ID: 23684942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular targeted therapy for the treatment of gastric cancer.
    Xu W; Yang Z; Lu N
    J Exp Clin Cancer Res; 2016 Jan; 35():1. PubMed ID: 26728266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.
    Young K; Chau I
    Drugs; 2016 Jan; 76(1):13-26. PubMed ID: 26620367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Met targeting in advanced gastric cancer: An open challenge.
    Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
    Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial Carcinoma: Specific Targeted Pathways.
    Eritja N; Yeramian A; Chen BJ; Llobet-Navas D; Ortega E; Colas E; Abal M; Dolcet X; Reventos J; Matias-Guiu X
    Adv Exp Med Biol; 2017; 943():149-207. PubMed ID: 27910068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
    Mabuchi S; Kuroda H; Takahashi R; Sasano T
    Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
    Brechbiel J; Miller-Moslin K; Adjei AA
    Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and II clinical trials for gastric cancer.
    Khushalani NI
    Surg Oncol Clin N Am; 2012 Jan; 21(1):113-28. PubMed ID: 22098835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.
    Kim C; Mulder K; Spratlin J
    Oncologist; 2014 Oct; 19(10):1046-55. PubMed ID: 25142842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    Slomovitz BM; Coleman RL
    Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
    Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting PI3K-AKT pathway for cancer therapy.
    Lu Y; Wang H; Mills GB
    Rev Clin Exp Hematol; 2003 Jun; 7(2):205-28. PubMed ID: 14763163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.